Cybin Announces Approval Of First In Human Dosing Of Its Proprietary Dmt Molecule Cyb004
By, Admin1 min read
Share
Cybin Announced That It Has Received Approval From An Independent Ethics Committee In The Netherlands To Initiate First-In-Human Dosing Of Its Proprietary Deuterated N,N-Dimethyltryptamine (
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
